Biotech Startups

Darmiyan develops brain-analysis technology for early detection of Alzheimer's disease. Its first product, BrainSee, aims to identify the disease at an early stage.

5 investors

Data-Driven Bioscience develops Duoseq, a cancer genomics platform that performs simultaneous DNA and RNA analysis from a single sample, delivering comprehensive molecular profiling results in two days for use in clinical diagnostics and research.

5 investors

DeepLife is an AI techbio company that develops digital twin technology to simulate cellular behavior and disease mechanisms at the single-cell level. The platform integrates multi-omics data and causal AI to accelerate drug discovery and development for diseases with significant unmet medical needs.

5 investors

Denali Therapeutics develops therapeutics for neurodegenerative diseases. The company focuses on discovering and developing novel drug candidates targeting specific neurological conditions.

5 investors

Dispersa is a biotechnology company that converts food waste into biodegradable biosurfactants for industrial applications. The company serves manufacturers seeking sustainable alternatives to petroleum-based and synthetic chemical surfactants.

5 investors

Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders. The company was founded by Cardiff University and SV Health Investors in 2024.

5 investors

The page presented is corporate content for Novartis, a pharmaceutical company that develops medicines across areas such as multiple sclerosis, cardiovascular disease, and oncology. The content covers clinical trial results, financial results, and annual reporting rather than the expected dtxpharma.com company.

5 investors

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform. The company focuses on discovery, clinical development, and commercialization of treatments for rare genetic disorders.

5 investors

A digital health resource platform providing medical professionals with educational information and clinical resources about transthyretin amyloid cardiomyopathy (ATTR-CM) and related cardiac and neurological conditions.

5 investors

Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment. The company explores and validates novel drug targets with a focus on breakthrough therapies addressing underlying disease pathology.

5 investors

Elektrofi is a biotech company developing an ultra-high concentration microparticle formulation platform that enables subcutaneous delivery of biologic medicines such as monoclonal antibodies. It partners with pharmaceutical companies to reformulate therapies for self-administration.

5 investors

EnClear Therapies is a bio/med-tech company developing the EnTrega CSF platform, focused on cerebrospinal fluid-related therapies. It is built by a multidisciplinary team with experience in platform and commercial market development.

5 investors

EndoGastric Solutions offers the Transoral Incisionless Fundoplication (TIF 2.0) procedure and the EsophyX device used to treat GERD, along with reimbursement and technical/administrative support (TAP program) for medical practices. The company, now associated with Merit Medical, serves gastroenterology and surgical providers performing anti-reflux procedures.

5 investors

Endomag makes the Magseed marker, a magnetic seed used to localize breast cancer lesions before and during surgery as an alternative to guidewire localization. It serves surgeons and radiologists treating breast cancer patients in the medical device field.

5 investors

EnduraTx develops small-molecule medicines that form permanent covalent bonds with disease-causing RNA to block production of proteins that cannot be drugged at the protein level, targeting conditions such as certain cancers and neurodegenerative diseases. Its TRANSCEND platform uses next-generation sequencing to map drug-RNA interactions at single-nucleotide resolution across many RNA targets simultaneously.

5 investors

Epicore Biosystems is a digital health company that develops wearable sweat-sensing devices measuring hydration, electrolyte loss, skin temperature, motion and other biomarkers. Its products serve industrial worker safety, sports and fitness performance, and clinical research applications, including a sweat patch developed with Gatorade.

5 investors

Euphrates Vascular develops the Pulse NanoMED System, a nanoscale interventional medical device that uses magnetically guided iron-oxide nanoparticles to reach and disrupt distal vascular occlusions beyond the reach of wires and catheters. The technology targets complex vascular occlusions, including stroke, for interventional and vascular treatment.

5 investors

Everbloom develops lab-grown noble fibers from protein waste as sustainable alternatives to animal and synthetic materials for luxury fashion. The company produces fibers with lower environmental impact than wool, cashmere, and silk across land use, water consumption, and emissions.

5 investors

Evozyne designs and builds engineered protein therapeutics using an AI-native platform, focusing on treatments for immune-mediated diseases. The company develops novel biologics and a pipeline of engineered proteins aimed at clinical use.

5 investors

EVQLV develops a computational platform for antibody discovery that uses machine learning and computational biology to accelerate and reduce the cost of generating fully-human antibodies for drug development. The platform serves pharmaceutical and biotech partners working on antibody therapeutics.

5 investors

Excelsior Sciences develops automated chemistry technology for small-molecule discovery and manufacturing, targeting pharmaceutical and materials development. Its proprietary Blocc Chemistry platform uses AI-guided synthesis to accelerate drug discovery through machine-readable chemical building blocks and closed-loop learning.

5 investors

5 investors

Exogene is a techbio startup using a generative AI and deep learning platform to discover novel, high-affinity TCR-based (T-cell receptor) therapies for treating solid tumors. It develops cell therapies aimed at cancer treatment by mining the TCR sequence space to identify safe, non-cross-reactive receptors against shared tumor targets.

5 investors

Exonate is a biotechnology company developing treatments for retinal vascular diseases, with a lead asset (EXN407) intended as a topical therapy for diabetic retinopathy and diabetic macular oedema. The drug is set to enter Phase IIb clinical trials in 2026.

5 investors